Optimal treatment for multistage N2-disease
Expert viewAims: To determine the prognosis of patients with stage III NSCLC and ipsilateral lymph nodes; to differentiate among types of N2 disease; to describe the different treatment modalities (surgery plus chemotherapy; surgery, chemotherapy and radiotherapy; radiochemotherapy, and radiochemotherapy plus PD-L1 inhibition) and their advantages and disadvantages in specific situations; to assess the relevance of a multidisciplinary tumour board for these patients; and to describe future developments in immunology